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Abstract- Congenital anomalies are the cause of 20.0-25.0% of cases of perinatal death, while 3.0% of children are born 
with malformations of varying size. We examined the predictive values and defined the credibility ratio of the combined 
test results. Sensitivity of the test is 94.0%, and specificity is 99.0%. The positive likelihood ratio [likelihood ratio test 
(LR+)] is 94.00; a negative likelihood ratio [likelihood ratio test (LR–)] is 0.06. The pretest probability that pregnant wom-
en carry a fetus with chromosomal abnormality is 1:250. Posttest odds after the combined test to discover this abnormality 
are 0.3760, and probability of the same case is 0.2732 if it happens that the test result is positive. The result of our study 
confirms the justification of combined test usage in routine clinical practice, since the posttest odds rate in the case of a 
positive screening increases several times over (almost 90 times); the probability of detecting a chromosomal abnormality 
was about 70 times.
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INTRODUCTION
Congenital anomalies cause 20.0-25.0% of perinatal 
deaths, while 3.0% of children are borne with malfor-
mations of varying size (Ebrahaim and al., 2000). An-
alytical immunochemiluminescence assays and an 
automated analyzer IMMULITE 2000 [Diagnostics 
Product Corporation (DPC), Los Angeles, Califor-
nia, USA] were used. Usable values of the combined 
test were estimated on the basis of its sensitivity, 
specificity and possibility of the disease in case the 
result was positive. By combining the values of preg-
nancy-associated plasma protein A (PAPP-A) and 
free β-subunit of choriogonadotropin (free β-HCG) 
in serum with nuchal translucency (NT) diameter 
(combined test), the possibility of detecting trisomy 
21 rises up to 90.0% with 5.0% false-positive findings 
(Alfirevic and Neilson, 2004). The testing was done 
between 11 and 13+6 weeks of gestation. If the result 
was positive, some invasive methods of prenatal di-
agnosis were suggested to the pregnant woman. A 
limit value of the combined test was 1: 250. A special 
problem was the test result interpretation. According 
to the literature, 32.0% of pregnant women did not 
know what the term “high risk” meant after getting 
the results and talking to the doctor (Spencer, 2001). 
The research objective was: 1) to examine the sensi-
tivity and specificity of ultrasonographic (NT) and 
biochemical (free β-HCG and PAPP-A) markers as 
parameters of the combined test, and amniocentesis 
in diagnostics of congenital fetal anomalies; and 2) to 
set the credibility ratio of the combined test results.
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MATERIALS AND METHODS
The prospective observational study was conduct-
ed at the Gynecology and Obstetrics Clinic at the 
Clinical Center Kragujevac (GOC, CC Kragujevac, 
Kragujevac, Serbia) during 2008 and 2009 on sin-
gleton intrauterine pregnancies in the first trimester 
of pregnancy. The clinical and experimental model 
of study was used throughout the research. The Eth-
ics Committee at the CC Kragujevac confirmed the 
correctness of this study and authorized its conduct. 
Three hundred and seventeen pregnant women were 
included in the examination and observed by the 
Board of Genetic Counseling at GOC, CC Kragu-
jevac. An informed consent form was signed by 
all participants. All ultrasound examinations were 
conducted on the Aloka Prosound 3500 Ultrasound 
Machine Package with UST-9124 (Aloka, Seoul, 
Suth Korea) at GOC, CC Kragujevac. Pregnancy was 
11-13+6 weeks of gestation. The crown-rump length 
(CRL) of the fetus was between 45 and 84 mm. While 
measuring fetal nuchal translucency (NT), we used 
an ultrasound apparatus of high resolution with the 
option “cine loop” so that the image could be turned 
by calipers that allow measurements of one decimal 
point. The screen image on which NT was measured 
encompassed only the head and the upper part of 
fetal rib cage. We used the maximum enlargement, 
so that small movements of the caliper altered the 
diameter by only 0.1 mm. The NT was measured by 
transvaginal approach of color Doppler technique 
with the fetus in a neutral position. We measured 
the maximal thickness of subcutaneous illumina-
tion between the skin and soft tissue located above 
the cervical part of the fetal spine. We set the cali-
pers on lines that define the fold, so that they were 
barely visible on the white limit line of the accumu-
lation behind the neck. During the examinations we 
conducted more measurements and took into con-
sideration only the highest thickness of the NT. We 
carried out the quantitative settings of free β-HCG 
and PAPP-A from the venous blood of patients by 
applying commercial tests from DPC. Tests were 
based on the analytical immunochemiluminescence 
assay and were realized by using the automated ana-
lyzer IMMULITE 2000 (DPC).
All the pregnant women included in this study 
underwent amniocentesis by a standard transab-
dominal procedure with ultrasound control using 
the “free hand” technique at 16 to 17+6 weeks of gesta-
tion. We did the puncture by needles with mandrene 
of 20-22G thickness and aspirated 15-20 mL of am-
niotic fluid into a syringe without a rubber seal. The 
amniotic fluid sample was delivered to the Cytoge-
netics Laboratory at the GOC, CC Kragujevac, and 
all results received were deposited into the unique 
database with the required logistic control.
RESULTS
After conducting the combined test in the total sam-
ple of pregnant women, we found the following indi-
vidual values of the examined parameters (see Table 
1): the statistically significant difference in values of 
free β-HCG and NT in the examined group of preg-
nant women was p <0.05. Parameter PAPP-A does 
not show any statistically significant difference in the 
examined group of pregnant women. We also found 
the same characteristics of the examined parameters 
in the receiver operating characteristic (ROC) curve 
analyses in the examination of the predictive charac-
teristics of the specified parameters (Figs. 1 and 2).
Analysis of the value distribution of the NT 
thickness measurement showed that the distribu-
tion was regular and that measurements were being 
set regularly around the median (44.0% below and 
56.0% above the median), which was in accordance 
with the criteria for quality control established by the 
Fetal Medicine Foundation (London, UK) and was 
supposed to be 40.0-60.0% above the median. The 
distribution of fetal NT for given CRL in examination 
was no different from the established distribution of 
the Fetal Medicine Foundation used as a standard. 
On the basis of that, our measurements of NT thick-
ness can be considered to be regularly conducted and 
usable in further examination.
The diameter of the NT did significantly statisti-
cally differ in the examined group of pregnant wom-
en (p<0.05). Crown-rump length and gestational age 
were not different statistically (p>0.05). Using the 
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contingency table (Table 2), we set the predictive 
value of the combination of ultrasonographic and 
biochemical markers after taking over the results of 
amniocentesis.
Estimation of probability that some disease is 
present before testing is called pretest probability 
(“a priori probability”). Pretest probability is re-
ceived on the basis of available information about 
the patient, including testing previous to the actual 
one. Estimation of the probability of disease after 
testing is called posttest probability (“a posteriori 
probability”). Posttest probability is less or higher 
than pretest probability depending on the test re-
sults. Measures of diagnostic accuracy (sensitivity, 
specificity) cannot directly answer the following 
important clinical questions: 1) if the disease pretest 
probability is known, and the examinee is positive 
on the test, what is the probability that he/she really 
has the disease? 2) If the disease pretest probability 
is known, and the examinee is negative on the test, 
what is the probability that he/she really does not 
have the disease?
These questions can be answered by the ap-
plication of the pretest odds of the disease and the 
credibility ratio. Disease odds ratio is the ratio of 
probability that the disease is present (p) and prob-
ability that is not present (1-p): odds = p/1-p. Ac-
cording to this, pretest disease odds are: pretest 
odds = pretest probability/1-pretest probability. 
Likelihood ratio (LR) is the probability ratio of a 
certain test result (+ or –) of the examinee who has 
the disease divided with the probability of the same 
result of the person who does not have the disease. 
Two types of likelihood can be calculated: 1) like-
lihood ratio of the positive test (LR+) is the ratio 
of sensitivity and false positive ratio (1–specificity): 
LR+ = sensitivity/1-specificity; 2) likelihood ratio 
of the negative test (LR–) the ratio of sensitivity and 
false negative ratio (1–sensitivity) and specificity: 
LR– = 1-sensitivity/specificity. The likelihood ratio 
shows how the test result can alter the pretest dis-
ease probability. The LR+ shows how much the test 
result increases disease probability, LR– shows how 
much the test result decreases disease probability. 
The likelihood ratios are not under the influence of 
the disease prevalence.
Fig. 1. Probability of the predictive value of free fraction β-HCG 
[field below ROC curve 0.846, 95% confidence interval (95% CI) 
0.628-1.064].
Fig. 2. Probability of the predictive value of PAPP-A [field below 
ROC curve 0.715 (95% CI 0.508–0.921)].
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Likelihood ratios can help measuring the posttest 
probability. How big the change from pretest to post-
test probability is depends considerably on the values 
of the likelihood ratio. It is desirable for (LR+) to have 
the highest values and (LR–) to have values closest 
to 0. For calculating the posttest disease probability, 
posttest odds are first to be calculated. 1) For posi-
tive test result: posttest odds = pretest odds x LR+; 2) 
for negative test result: posttest odds = pretest odds x 
LR–. Posttest probability is obtained by the formula: 
posttest probability = posttest odds/1+ posttest odds. 
According to the literature data, the diagnostic ac-
Table 1. Difference between values of free β-HCG, PAPPA and NT in 317 pregnant women (total sample).
Parameters Free β-HCG (mL/mL) PAPP-A (mL/mL) NT (mm)
Pathological karyotype 114.00 1.36 2.55
Physiological karyotype 19.20 1.84 1.90
Mann-Whitney test (U) 704.50 2191.00 621.50
p Value 0.000 0.543 0.000
Table 2. Review of the middle values (MV) and standard deviations (SD) of the ultrasonographic parameters and gestational age in 317 
pregnant women
Parameters Pathological Karyotype: 16 Control Group: 301 p Value
Nuchal translucency (mm) 2.49 ± 0,37 1.92 ± 0,39 <0.05
Crown-rump-length (mm) 60.12 ± 8.48 64.83 ± 8.23 >0.05
Gestational age (days) 86.69 ± 3.98 87.40 ± 7.40 >0.05
Table 3. Contingency table created on the basis of data processing in the total sample of pregnant women after amniocentesis
Test Result Disease Present Disease Absent Total
Positive Really positive: 15 False-positive: 1 RP+FP: 16
Negative False-negative: 3 Really negative: 298 FN+RN: 301
Total 18 299 317
Table 4. Probability and predictive values of the parameters of the combined test in relation to result of early amniocentesis
Parameter p Value 95% CI
Sensitivity 0.9375 0.6977-0.9984
Specificity 0.9900 0.9712-0.9979
Positive predictive value 0.8333 0.5858-0.9642
Negative predictive value 0.9967 0.9815-0.9999
Prevalence 0.0505 0.0291-0.0807
False-positive rate 0.0100 0.0046-0.245
False-negative rate 0.0625 0.0145-0.0998
Positive likelihood ratio (LR+) 94.0000 30.2937-292.0653
Negative likelihood ratio (LR–) 0.0631 0.01746-1.2712
Overall test accuracy 0.9873 0.07215-0.9981
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curacy of the combined test, in relation to the result 
of the early amniocentesis (referral standard) is: sen-
sitivity 0.88, specificity 0.90. In our sample sensitiv-
ity is 0.94 and specificity 0.99. Likelihood ratios are: 
LR+ = 0.94/1-0.99 = 94.00; LR– = 1-0.94/0.99 = 0.06. 
Pretest probability that the pregnant woman car-
ries a fetus with chromosomal abnormality is 1:250 
= 0.004. Pretest odds = 0.004/0.996 = 0.004. If the 
test is positive: posttest odds = pretest odds x LR+ = 
0.004 x 94 = 0.3760; posttest probability = posttest 
odds/1+ posttest odds = 0.3760/1+0.3760 = 0.2732. 
If the test is negative: posttest odds = pretest odds x 
LR– = 0.004 x 0.06 = 0.00024. Posttest probability = 
posttest odds/1+posttest odds = 0.00024/1+0.00024 
= 0.00024.
DISCUSSION
In our study, we had nine (2.84%) pregnant women 
with numeric aberrations in total and seven (2.21%) 
pregnant women with structural aberrations in fe-
tuses which could be explained by the fact that the 
sample was preselected. All pregnant women were 
sent to Genetic Counseling at the GOC, CC Kragu-
jevac (Table 2), for some suspected reason (positive 
personal and/or family case history, age of the preg-
nant woman, likelihood of giving birth to a child with 
chromosomal aberrations and/or fetal anomalies in 
previous pregnancies, etc.). Similar results were re-
ported in the study conducted in Great Britain in 
2000 which stated that the total incidence of Down’s 
syndrome was 1 in 1,000 deliveries, which was 50.0% 
more than in the national reports (Wald et al., 1999). 
The importance of NT measurement in the screen-
ing for Down’s syndrome during the first trimester of 
the pregnancy was recognized back in 1990. With a 
limit value of 3 mm NT thickness, the detection rate 
(DR) is 64.0% (Wald et al., 2003). Screening sensi-
tivity of chromosomopathies in comparison to NT 
was 75.0% with a value of false-positive ratio of 2.1% 
(Stojiljkovic-Mikic and Rodeck, 2003). In our sam-
ple, 11 pregnant women in total from the group of 
16 had a measured value of NT above the median for 
the given CRL in the group of pathological karyo-
types that was 68, i.e. 75.0%. By the analysis of the 
total sample, we found that with 26 pregnant women 
we measured a NT of 2.55 mm above median for the 
given CRL and by invasive diagnostics we confirmed 
16 cases of chromosomal fetal aberrations (61.54%) 
(Table 3). The methodology of the combined test 
(Table 1) indicated that the ultrasound screening 
was done first, and after that the level of free β-HCG 
and PAPP-A was set, where risks are calculated as 
the combination of the two data (Haddow et al., 
1998). For a certain gestation time, the levels of free 
β-HCG and PAPP-A represent the factor of probabil-
ity, which is multiplied by the initial risk in order to 
calculate a new risk (Wald et al., 1996). Differences 
in the concentration of free β-HCG between normal 
pregnancies and those with trisomy 21 increase, and 
differences in the level of PAPP-A decrease, with the 
age of the pregnancy. There is no significant connec-
tion between thicknesses of the fetal NT, level of free 
β-HCG or PAPP-A in maternal serum in pregnan-
cies with trisomy 21 in relation to normal pregnan-
cies, so ultrasound and biochemical markers can be 
combined in order to get more efficient screening re-
sults. Numerous studies have confirmed the connec-
tion between the low level of PAPP-A and trisomy 
21 during the first trimester (Alfirevic and Neilson, 
2004). In normal pregnancies, the level of PAPP-A 
in maternal blood increases with gestation time, and 
in pregnancies with trisomy 21 it decreases [multi-
ple of median (MoM)] (<0.5). By setting the value of 
PAPP-A, it is possible to detect 52.0% of Down’s syn-
drome cases with 5.0% false-positive results (Alfirev-
ic and Neilson, 2004). In pregnancies with trisomy 
21, the level of free β-HCG is increased between 8 
Table 5. Influence of the combined test on the pretest odds and 
probability of the outcome in relation to the likelihood ratio in 
case of positive and negative outcome
Parameter p Value
Pretest odds/probability 0.0040
Posttest odds/positive test 0.3760
Posttest odds/negative test 0.0002
Likelihood ratio/LR+ 94.000
Likelihood ratio/LR– 0.0600
Posttest probability/positive test 0.2732
Posttest probability/negative test 0.0002
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and 14 weeks of gestation. The level of free β-HCG 
in maternal blood decreases normally with gestation 
time, and in pregnancies with trisomy 21, the level 
of free β-HCG increases (MoM >2.0) (Snijders et 
al., 1996; Cunningham et al., 2005). On the basis of 
free β-HCG level, DR amounts to 42.0% with 5.0% 
false-positive findings (Wellesley et al., 2002). The 
frequency of false-positive results, according to the 
available literature, is estimated at 5.0% (Loncar et 
al., 2010; Hallahan et al., 2000; Brigatti and Malone, 
2004; Nicolaides, 2004). Our research has shown 
that the rate of false-positive findings is 1.0%, and 
that free β-HCG is a more sensitive predictor than 
PAPP-A. Other investigators have reported identical 
conclusions (Brigatti and Malone, 2004). The predic-
tive value of the individual biochemical markers is 
represented in Charts 1 and 2 by setting the area be-
low the ROC curve. On reviewing the combined test 
predictive value of our sample of pregnant women, 
we found the following results: sensitivity of the test 
is 94.0%, specificity is 99.0%. The positive predictive 
value of the test is 0.83, and negative predictive value 
of the test is 0.99 (99.0%). The positive likelihood ra-
tio (LR+) is 94.00 and negative likelihood ratio (LR–) 
is 0.06 (Tables 4 and 5). We have already confirmed 
the published positive qualifications of this screening 
method (Spencer et al., 1999)  and point to its justi-
fication in every day clinical practice (Krantz et al., 
2000).  Regarding posttest odds, the rate in the case 
of positive screening increases several times over (al-
most 90 times). In the available literature, we have 
not found any reports that have the calculation of 
the credibility of the combined test and prediction 
of posttest odds of this screening method. It is most 
important to tell the patients that this is a process of 
screening and not a final diagnosis. This can be given 
only on the basis of invasive intervention and defin-
ing of the fetal karyotype (Spencer, 2000).
CONCLUSIONS
By examining the sensitivity and specificity of the 
combined screening test in the period of 11.-13+6 
weeks gestation, we found that the sensitivity of the 
test was 0.94 (94.0%), and its specificity 0.99 (99.0%). 
Pretest probability that a pregnant woman carries a 
fetus with a chromosomal abnormality is 1:250 or 
0.004. Posttest odds after the combined test to dis-
cover this abnormality were 0.3760, and the prob-
ability of the same case was 0.2732 if the test result 
was positive. Posttest odds after the combined test 
and the probability of the same case were identical if 
the test result was negative and amounted to 0.0002.
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